Remdesivir powers activate! Wouldn’t it be great if remdesivir magically cured COVID-19? Too bad it doesn’t. So what should we be willing to pay for a drug that shortens hospital stays and might reduce mortality? In this episode of HealthBiz, physician and healthcare executive Surya Singh shares his take on drug pricing, ICER and the future of the pandemic.
- Surya’s LinkedIn profile
- Institute for Clinical and Economic Review (ICER) remdesivir pricing model
- Letter from State Attorneys General about remdesivir pricing
- Boston Globe article comparing MA and RI school reopening plans
- Inspiration for “Remdesivir power, activate!”
- Health Business Group
- David’s LinkedIn profile